UK liquid biopsy firm partners to customise cancer treament
Cambridge-based liquid biopsy firm Inivata is set to partner with oncology support company N-of-One to create individualised patient profiles based on genomic information, with treatment options and suggestions for clinical trials. The results of Inivata's ctDNA liquid biopsy test, used to detect cancer, stratify patients and assess individual response to treatment will be integrated into N-of-One's proprietary database, where oncologists can access a patient’s "unique molecular profile" and determine treatments and introduction into clinical trials accordingly.

Something went wrong, please try again later.

Invalid email Something went wrong, please try again later.

Sign up to our free email newsletter to receive the latest breaking news and daily roundups

Liquid biopsy firm Inivata has signed a new partnership which will see it providing personalised genomic interpretation and clinical trial matching for cancer patients.

It is hoped the partnership with N-of-One, a precision medicine oncology decision support company, will enable the delivery of clear, easy to interpret patient reports, providing physicians with a wealth of genomic information.

The collaboration will provide each physician with an individualized liquid biopsy report based on their cancer patient’s unique genomic signature. N-of-One’s oncologists and scientists will also provide the analysis needed to assess current treatments, analyse potential novel mutations and allow the oncologists to make more informed decisions for treatment strategies. Inivata has also recently announced the launch of a large-scale, prospective clinical validation study in non-small cell lung cancer and additional studies are currently underway.

“N-of-One’s experience in curating complex genomic information and translating this data into clinically relevant results on tens of thousands of patients has enabled them to develop a market-leading database and unparalleled expertise. We are excited to access their capabilities to ensure we provide physicians with the most actionable information in our easy to interpret report,” said Michael Stocum, CEO of Inivata.

The plan is for N-of-One to support Inivata’s liquid biopsy assay by providing oncologists and pathologists with the most relevant oncology treatment options through the analysis of each patient’s unique molecular profile.

The N-of-One solution will integrate the interpretation of multiple molecular tests on a patient to provide a comprehensive view of the cancer and, leveraging N-of-One’s proprietary database, will identify individualised treatment options, including clinical trials for consideration by the oncologist. The company’s experience in oncology, and specifically liquid biopsies, makes them uniquely capable of interpreting the Inivata liquid biopsy test, Inivata says.

“We are pleased to partner with Inivata in support of the launch of their revolutionary ctDNA platform capabilities,” said Chris Cournoyer, CEO of N-of-One.

“Pairing Inivata’s highly sensitive analysis of actionable mutations with N-of-One’s ability to analyze the data of novel mutations has the potential to help guide more personalized treatment decisions for patients prior to and throughout the cancer care continuum.”

Inivata uses ultra-sensitive ctDNA analysis to improve personalized healthcare in oncology. Based on a simple blood test, ctDNA analysis is a new tool for oncologists to detect cancer, stratify patients, and assess individual response to treatment. The company, which is based at the Li Ka Shing Centre on Robinson Way, utilises proprietary technology which is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK’s Cambridge Institute.